Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
124 participants
INTERVENTIONAL
2015-10-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy
NCT02611271
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
NCT01400893
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
NCT05758077
Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis
NCT06253377
Investigating Different Anticoagulants for Renal Replacement Therapy
NCT02669589
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One group is treated with CVVHD/ local citrat anticoagulation (standart clinical practice).
The other group ist treated with an additional cytokine adsorber ( 300ml CytoSorb device, 3804606CE01)
CytoSorb therapy is performed for 24h, then the adsorber is changed into a new device.
Cytosorb therapy is stopped, when Interleukin 6 leves drop below 1000 pg/ml in patient serum.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intervention
Standart CVVHD plus CytoSorb 300 ml device (3804606CE01)
CytoSorb 300 ml device (3804606CE01)
additional cytokine adsorber
control
Standart CVVHD
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CytoSorb 300 ml device (3804606CE01)
additional cytokine adsorber
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technical University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guenther_Edenharter
Dr.med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kochs Eberhard, Chairman
Role: STUDY_CHAIR
Department of Anaesthsiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinik für Anästhesiologie
München, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
316/15 S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.